Patient and Provider perspectives on long acting injectable ART

摘要 长效注射抗逆转录病毒疗法(LAI ART)有望成为 艾滋病毒感染的管理。然而，这一治疗创新将如何在患者和 供应商仍不清楚。目前，几乎没有数据可以用来预测，更不用说计划合并了 将艾滋病毒护理的这一创新付诸实践。我们的初步研究显示，人们对赖艺术感到兴奋 参与这种抗逆转录病毒药物管理模式的研究试验的参与者，在艾滋病毒护理中可能热情较低 供应商。通过建议的研究研究，我们寻求对这些认知的更深入的理解 关于LAI ART在美国不同的PLHIV群体及其护理提供者中的应用。这一理解将 用于通知LAI抗逆转录病毒疗法的推出，包括开发艾滋病毒/艾滋病和艾滋病提供者可使用的工具 以指导在选择治疗方案时的共享决策。

ABSTRACT Long-acting injectable antiretroviral therapy (LAI ART) is anticipated to be a major advance in the management of HIV infection. However, how this therapeutic innovation will be received among patients and providers remains unclear. At present, there are few data with which to forecast, let alone, plan for incorporation of this innovation in HIV care into practice. Our preliminary studies demonstrate excitement for LAI ART among participants in research trials of this mode of ART administration, with possibly less enthusiasm among HIV care providers. With the proposed research studies, we seek to gain a deeper understanding of the perceptions regarding LAI ART among diverse groups of PLHIV in the US and their care providers. This understanding will be used to inform the roll-out of LAI ART, including the development of tools that PLHIV and providers can use to guide shared decision-making when choosing among treatment options.